Immunomagnetic CD4+ and CDS+ cell depletion for patients at high risk for severe acute GVHD

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 377-382

  Jansen, J ^a   Hanks, S ^a   Akard, L P ^a   Thompson, J M ^a   Burns, S ^a   Chang, Q ^a   English, D ^a   Garrett, P ^a  

^a METHODIST HOSPITAL   (United States)

Author keywords

GVHD; Magnetic beads; T cell depletion; Unrelated BMT

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL SEPARATION; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA; MALE; PRIORITY JOURNAL; RELAPSE; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; FEVER; GRAFT VS HOST DISEASE; HUMANS; IMMUNOMAGNETIC SEPARATION; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SYNDROME; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029965153     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft vs host disease. In: Burakoff HSJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft vs Host Disease. Immunology, Pathophysiology, and Treatment. Marcel Dekker: New York, 1990, pp 331-335.
2. Vallera DA, Soderling CCB, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 1981; 31: 218-222.
3. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185-192.
4. Patterson J, Prentice HG, Brenner MK et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 6: 221-230.
5. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
6. + T lymphocytes for prevention of graft-versus-host disease after allogenic bone marrow transplantation. Blood 1990; 76: 418-423.
7. + cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57: 82-87.
8. Champlin R, Jansen J, Ho W et al. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991; 23: 1695-1696.
9. Jansen J, Hanks S, Akard L et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 271-278.
10. Janossy G, Tidman N, Papageorgion ES et al. Distribution of T-lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. J Immunol 1981; 126: 1608-1613.
11. Ash RC, Casper JT, Chitamber CR et al Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 1990; 322: 485-494.
12. - T cells repopulate at different rates after allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 291-296.
13. - and γδT-cell receptor positive T lymphocytes. Clin Exp Immunol 1989; 80: 114-121.
14. Storb R, Deeg J, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
15. Essel JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784-2788.
16. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-550.
17. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207-214.
18. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993: 328: 593-602.
19. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from unrelated donors other than HLA-identical siblings. New Engl J Med 1985; 313: 765-771.
20. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249-253.